Literature DB >> 21153576

[Pigment epithelial detachment in exudative macular degeneration: clinical characteristics and therapeutic options].

A Lommatzsch1.   

Abstract

Vascularized pigment epithelial detachment (PE detachment) can be viewed as a special form of occult choroidal neovascularization (CNV) owing to the natural course of the disease, its specific pathogenesis and its response to various forms of treatment. This applies to serous PE detachment associated with both occult CNV and also with retinal angiomatous proliferation (RAP). A tear in the retinal pigment epithelium (RIP) represents a serious complication of vascularized PE detachment and is often associated with acute vision deterioration that not uncommonly also involves massive subretinal hemorrhaging. The pathomechanism underlying the development of RIP has not yet been completely elucidated. The notion that the PED bursts as a result of the increased pressure stands in contrast to the theory that the CNV contracts and causes scarring which in turn causing secondary RIP. Anti-VEGF therapy is currently the preferred treatment. However, the initial stabilization of visual acuity after treatment could not be confirmed in long-term studies and after 2 years visual acuity deteriorated significantly. Furthermore, optimal VEGF treatment regimens have also not been defined and the criteria for repeated treatment have not been established as yet. Presently, visual deterioration and the presence of subretinal and intraretinal exudates seem to indicate that treatment will be effective. Here, high resolution OCT imaging should help to provide further insight into the matter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153576     DOI: 10.1007/s00347-010-2143-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  71 in total

1.  [Association between classic cardiovascular risk factors and age-related maculopathy (ARM). Results of the baseline examination of the Münster Aging and Retina Study (MARS)].

Authors:  B Dasch; A Fuhs; A Meister; T Behrens; K Krause; D Pauleikhoff; H W Hense
Journal:  Ophthalmologe       Date:  2005-11       Impact factor: 1.059

2.  Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2005-12-19       Impact factor: 12.079

Review 3.  [Age-related macular degeneration. 1. Epidemiology, pathogenesis and differential diagnosis].

Authors:  D Pauleikhoff; F G Holz
Journal:  Ophthalmologe       Date:  1996-06       Impact factor: 1.059

4.  Health maintenance issues of the elderly. Vision: age-related macular degeneration.

Authors:  S B Bressler
Journal:  Md Med J       Date:  1989-02

Review 5.  Retinal pigment epithelial detachments in the elderly.

Authors:  A C Bird; J Marshall
Journal:  Trans Ophthalmol Soc U K       Date:  1986

6.  A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.

Authors:  Anne E Hughes; Nick Orr; Hossein Esfandiary; Martha Diaz-Torres; Timothy Goodship; Usha Chakravarthy
Journal:  Nat Genet       Date:  2006-09-24       Impact factor: 38.330

7.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

Review 8.  Preventative ophthalmology. Age-related macular degeneration.

Authors:  N M Bressler; S B Bressler
Journal:  Ophthalmology       Date:  1995-08       Impact factor: 12.079

9.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

10.  Complement factor H variant Y402H and basal laminar deposits in exudative age-related macular degeneration.

Authors:  Albrecht Lommatzsch; Pia Hermans; Bernhard Weber; Daniel Pauleikhoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-18       Impact factor: 3.117

View more
  5 in total

1.  [Forms of age-related macular degeneration].

Authors:  M Schargus
Journal:  Ophthalmologe       Date:  2015-04       Impact factor: 1.059

2.  [Change of therapy from ranibizumab to aflibercept for recurrent or persistent exudative age-related macular degeneration].

Authors:  M Ziegler; B Heimes; B Book; M Dietzel; M Zeimer; G Spital; M Gutfleisch; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2015-05       Impact factor: 1.059

3.  [Serous vascularized pigment epithelial detachment in exudative AMD. Morphological typing and risk of tears in the RPE].

Authors:  B Lehmann; B Heimes; M Gutfleisch; G Spital; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2015-01       Impact factor: 1.059

4.  [Tear in the retinal pigment epithelium by intravitreal injection of aflibercept].

Authors:  T Bertelmann; W Sekundo; Y Wenner
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

5.  The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.

Authors:  Ozlem Dikmetas; Sibel Kadayıfcılar; Bora Eldem
Journal:  Mol Vis       Date:  2013-12-20       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.